Product Data Sheet



®

ODN 20844

Cat. No.:	HY-150736	
CAS No.:	1964506-29-3	
Molecular Weight:	4872.9	
Sequence:	DNA, d(P-thio)(T-C-C-T-G-G-C-G-c7G-G-G-A-A-G-T)	DNA, d(P-thio)(T-C-C-T-G-G-C-G-c ₇ G-G-G-A-A-G-T)
Target:	Toll-like Receptor (TLR)	
Pathway:	Immunology/Inflammation	
Storage:	-20°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro

 $H_2O :\ge 20 \text{ mg/mL} (4.10 \text{ mM})$

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	1 mg	5 mg	10 mg
	1 mM	0.2052 mL	1.0261 mL	2.0522 mL
	5 mM			
	10 mM			

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY					
Description	ODN 20844, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a TLR7 and TLR9 (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 20844 disrupts TLR7- and TLR9-mediated immune cell immune responses. ODN 20844 sequence: 5'-TCCTGGCGc7GGGAAGT-3' ^[1] .				
IC ₅₀ & Target	TLR7	TLR9			
In Vitro	ODN 20844 (0.01-10 μM, 24 h) can effectively block TLR9-mediated IFN-α release and inhibit IL-6 secretion in human peripheral blood mononuclear cells ^[1] . ODN 20844 (0.01-10 μM, 24 h) has better inhibitory effect on imiquimod-induced IL-6 secretion in human B cells than INH-ODN 2088 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

REFERENCES

[1]. Franziska Römmler, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015 Feb 19;10(2):e0116703.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA